Cybin Inc. (NYSE:CYBN – Get Free Report)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $9.78, but opened at $9.30. Cybin shares last traded at $9.70, with a volume of 26,558 shares traded.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cybin in a research note on Friday, August 23rd. Canaccord Genuity Group lowered their price objective on shares of Cybin from $114.00 to $96.00 and set a “buy” rating for the company in a research note on Monday, September 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cybin in a research note on Wednesday, July 31st.
Get Our Latest Research Report on Cybin
Cybin Stock Down 1.2 %
Cybin (NYSE:CYBN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. As a group, analysts expect that Cybin Inc. will post -2.85 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in CYBN. Sanctuary Advisors LLC acquired a new stake in shares of Cybin in the 2nd quarter valued at $36,000. AdvisorShares Investments LLC lifted its holdings in Cybin by 13.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock worth $494,000 after buying an additional 220,403 shares during the last quarter. Rosalind Advisors Inc. boosted its position in shares of Cybin by 38.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock worth $5,230,000 after acquiring an additional 5,340,000 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Cybin in the 1st quarter valued at about $24,041,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Cybin during the 1st quarter worth about $5,770,000. Institutional investors and hedge funds own 17.94% of the company’s stock.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
See Also
- Five stocks we like better than Cybin
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Bank of America Earnings Uncover Shifts in Consumer Spending
- What is a support level?
- NVIDIA Stock Continues to Be Wall Street’s Favorite: Here’s Why
- What Does a Stock Split Mean?
- Cavco’s Future Looks Bright as Affordable Housing Demand Soars
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.